{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T11:37:20Z","timestamp":1792496240424,"version":"4.5.0"},"reference-count":37,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To describe trends in the use of anti\u2010obesity drugs in Norway during the period 2004\u20132022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We assessed the annual utilization of any available drug indicated for obesity recorded in the nationwide Norwegian Prescribed Drug Register for adults (age 18\u201379\u2009years) from 1 January 2004 to 31 December 2022. Prevalence was stratified by sex and age group (18\u201329\u2009years and 10\u2010year age groups thereafter). Additional analyses were performed in individuals initiating treatment with an anti\u2010obesity drug and on the cost of the anti\u2010obesity drugs since 2017.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The prevalence of anti\u2010obesity drug use decreased from 2009, when sibutramine and rimonabant were withdrawn from the market, and increased again after the approval of bupropion\u2010naltrexone in 2017 and liraglutide in 2018. The use of the peripheral\u2010acting anti\u2010obesity drug orlistat decreased from 2004. In 2022, 1.04% of the adult Norwegian population (72.8% women) filled at least one prescription of bupropion\u2010naltrexone, 0.91% used liraglutide (Saxenda; 74.2% women), and semaglutide without reimbursement was used by 0.68% (76.7% women). The prevalence increased with age, peaking in the age group 50 to 59\u2009years, and decreased in older age groups. From 2017 to 2022, 2.8% of the adult residents initiated treatment with an anti\u2010obesity drug. The total sale of those drugs increased from 1.1 million euros in 2017 to 91.8 million euros in 2022.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The use of anti\u2010obesity drugs in Norway has increased substantially in recent years, especially among women aged 40 to 59\u2009years. Changes in availability and reimbursement have influenced the use of these drugs in recent years.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.15515","type":"journal-article","created":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T02:16:01Z","timestamp":1709172961000},"page":"2102-2110","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pharmacological treatment of obesity in adults in Norway 2004\u20132022"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3404-2060","authenticated-orcid":false,"given":"Paz Lopez\u2010Doriga","family":"Ruiz","sequence":"first","affiliation":[{"name":"Department of Chronic Diseases Norwegian Institute of Public Health  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d8ystein","family":"Karlstad","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases Norwegian Institute of Public Health  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjersti","family":"N\u00f8kleby","sequence":"additional","affiliation":[{"name":"Department of General Practice University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Sl\u00e5tsve","sequence":"additional","affiliation":[{"name":"Department of Medicine Nordlandsykehuset HF  Bod\u00f8 Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanne L.","family":"Gulseth","sequence":"additional","affiliation":[{"name":"Division of Mental and Physical Health Norwegian Institute of Public Health  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haakon E.","family":"Meyer","sequence":"additional","affiliation":[{"name":"Department of Physical Health and Ageing Norwegian Institute of Public Health  Oslo Norway"},{"name":"Department of Community Medicine and Global Health University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari Anne","family":"Sveen","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Preventive Medicine and Morbid Obesity Oslo University Hospital  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Qvigstad","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Preventive Medicine and Morbid Obesity Oslo University Hospital  Oslo Norway"},{"name":"Institute of Clinical Medicine, University of Oslo  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari","family":"Furu","sequence":"additional","affiliation":[{"name":"Department of Chronic Diseases Norwegian Institute of Public Health  Oslo Norway"},{"name":"Centre for Fertility and Health Norwegian Institute of Public Health  Oslo Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,28]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"WHO.Obesity and Overweight. Retrieved fromhttps:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/obesity-and-overweight"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30054-X"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41574\u2010019\u20100176\u20108"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213\u20108587(22)00033\u2010X"},{"key":"e_1_2_9_6_1","unstructured":"World Obesity.World Obesity Atlas.2022. Retrieved fromwww.worldobesity.org\/resources\/resource\u2010library\/world\u2010obesity\u2010atlas\u20102022"},{"key":"e_1_2_9_7_1","unstructured":"AbelMH TotlandTH.Kartlegging av kostholdsvaner og kroppsvekt hos voksne i Norge basert p\u00e5 selvrapportering\u2013Resultater fra Den nasjonale folkehelseunders\u00f8kelsen 2020.2021."},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(22)02403\u20105"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19897"},{"key":"e_1_2_9_10_1","volume-title":"Endotext [Internet]","author":"Tchang BG","year":"2021"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2009.00494.x"},{"issue":"2","key":"e_1_2_9_12_1","first-page":"129","article-title":"Establishment of the nationwide Norwegian prescription database (NorPD): new opportunities for research in pharmacoepidemiology in Norway","volume":"18","author":"Furu K","year":"2008","journal-title":"Nor Epidemiol"},{"key":"e_1_2_9_13_1","unstructured":"Statistics Norway.Statistics Norway Population. Retrieved fromhttps:\/\/www.ssb.no\/en\/befolkning\/folketall\/statistikk\/befolkning"},{"key":"e_1_2_9_14_1","unstructured":"Norwegian Institute of Public Health.Wholesaler\u2010based drug statistics. Retrieved fromhttps:\/\/www.fhi.no\/en\/he\/drug\/om-den-grossistbaserte-legemiddelforbruksstatistikken\/"},{"key":"e_1_2_9_15_1","unstructured":"Norwegian Medicines Agency.The Norwegian health care system and pharmaceutical system. Retrieved fromhttps:\/\/www.legemiddelverket.no\/en\/about\u2010us\/the\u2010norwegian\u2010health\u2010care\u2010system\u2010and\u2010pharmaceutical\u2010system"},{"key":"e_1_2_9_16_1","unstructured":"Helsenorge.Livsstilsendring og vektreduserende medisiner. Retrieved fromhttps:\/\/tjenester.helsenorge.no\/samvalg\/sykelig-overvekt\/livsstilsendringer-og-vektreduserende-medisiner"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14367"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11695\u2010020\u201004987\u20102"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22581"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13679\u2010021\u201000453\u2010x"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40618\u2010023\u201002196\u2010z"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13679\u2010020\u201000398\u20107"},{"key":"e_1_2_9_23_1","unstructured":"KyleT GoldenA.We have better obesity medications but access is lagging. Clinical Advisor.2023."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/asj\/sjad211"},{"issue":"6","key":"e_1_2_9_25_1","first-page":"511","article-title":"Weight\u2010loss drugs\u2013for whom, how, how long?","volume":"142","author":"Hjelmes\u00e6th J","year":"2022","journal-title":"Tidsskr Nor Laegeforen"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-018-3525-0"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)01640\u20108"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-6625-3_55-1"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1159\/000442721"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.307.6908.846"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573\u2010021\u201000337\u20108"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2022.100018"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003114"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/432607"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261\u2010022\u201001202\u20101"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19574"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010022\u201002026\u20104"},{"key":"e_1_2_9_38_1","unstructured":"European Medicines Agency.CHMP post authorisation summary of positive opinion for Mounjaro (II\u201007).2023. Retrieved fromhttps:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries\u2010opinion\/mounjaro"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.15515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:38:58Z","timestamp":1761881938000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.15515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,28]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["10.1111\/dom.15515"],"URL":"https:\/\/doi.org\/10.1111\/dom.15515","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.15515\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15515\/v1\/review4","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15515\/v1\/review3","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15515\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15515\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15515\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15515\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15515\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15515\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,28]]},"assertion":[{"value":"2023-12-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}